| Today’s Big NewsApr 19, 2024 |
| By Nick Paul Taylor Immunology is AbbVie’s world, everyone else just lives in it. That is the takeaway from ZoomRx’s analysis of the perceptions of healthcare professionals , who overwhelmingly see AbbVie as the top dog in a field targeted by rivals such as Pfizer and Johnson & Johnson. |
|
|
|
By Annalee Armstrong Vir Biotechnology conducted a world-wide search to find the perfect CEO. In the end, the board picked Bayer’s Marianne De Backer because of her three decades of experience in the pharmaceutical industry and her “deep and thorough understanding of the evolving healthcare landscape.” |
By Fraiser Kansteiner Nearly a year and a half after FibroGen slapped a pair of former employees with a lawsuit alleging trade secrets theft, both the plaintiffs and the defendants are walking away from the case little worse for wear. |
By Max Bayer Sanofi's global restructuring is becoming clearer, with employees in Belgium the latest to be impacted. The French pharma expanded its footprint in Ghent after acquiring Ablynx in 2018. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Conor Hale The injectable Lumisight agent was approved via the FDA’s drug review pathway, while the visualization system took a parallel track through the agency's device center. |
By Angus Liu Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured an FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. |
By Angus Liu Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company's acquisition of Horizon Therapeutics. |
By Eric Sagonowsky During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. A spokesperson said the company would offer affected employees a chance to apply for new roles, plus "outplacement services." |
By Andrea Park As industries around the globe wrestle with where and how often artificial intelligence should be implemented in their workflows, biopharma, for one, is proceeding with caution. |
By James Waldron Barinthus Biotherapeutics has hit the primary endpoint of a phase 1b/2 trial by showing its treatment for high risk human papillomavirus-associated cervical cancer is safe. But the failure to prove the therapy actually works has left the biotech mulling how to take the candidate further. |
By Kevin Dunleavy CSL Vifor has proposed to launch a campaign that would undo the potentially misleading messages it sent about the safety of a rival product, the European Commission (EC) said. The initiative comes nearly two years after the EC launched an investigation surrounding Vifor’s alleged efforts to disparage the safety of Pharmacosmos’ intravenous iron deficiency treatment Monifer—which competes one-on-one with Vifor’s blockbuster Ferinject. |
By Nick Paul Taylor AstraZeneca has tapped an ice hockey player who knows a thing or two about checking for the latest spin on its NHL-partnered “Get Body Checked Against Cancer” campaign. The hard-hitting New York Rangers captain Jacob Trouba is fronting the campaign with his mother, Kristy, to encourage cancer screening. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
|
Monday, April 29, 2024 | 12:30pm ET / 9:30am PTLearn how evolving healthcare delivery impacts product positioning for Integrated Delivery Networks. Discover key messages, stakeholders, and shifts in IDN perceptions post-COVID-19. Claim your spot.
|
|
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
